This report was first published by Endpoints News. To see the original version, click here
Richard Pazdur doesn’t regret resigning back in December as director of the FDA’s drug center, just weeks after taking the role.
Pazdur, who spent more than two decades leading the agency’s cancer drug reviews, left the post of Center for Drug Evaluation and Research director abruptly. In an interview with Endpoints News, he pointed to several issues with FDA Commissioner Marty Makary’s priorities and specifically highlighted the unprecedented political interference in the FDA’s drug reviews.
您已阅读11%（586字），剩余89%（4959字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。